急性心肌梗塞院前重组链激酶的溶栓与救治的临床观察

目的探讨院前溶栓与住院溶栓的急性心肌梗塞(AMI)患者临床疗效,并探讨院外AMI患者溶栓治疗的可行性、安全性。方法110例AMI患者被随机分为院前溶栓组54例和入院后溶栓组56例。接受过院外救治的54例诊断AMI后立即给重组链激酶150万U静脉点滴,同期住院治疗的56例AMI患者诊断后按上述方法立即溶栓。结果确诊为AMI溶栓时间:院外溶栓组为(1.48±0.46)h,院内溶栓组为(2.68±1.98)h。按临床标准判断冠状动脉总再通率:院前溶栓组80.8%(42/52),2例死亡;院后溶栓组64.1%(34/53),3例死亡(P<0.05)。结论入院前溶栓明显缩短AMI患者开始溶栓的时间,增加冠状动脉的再通率,安全可行。

Objective To investigate the pre-hospital thrombolysis and hospital thrombolysis in acute myocardial infarction （AMI） clinical efficacy, and to explore outside of the hospital thrombolytic therapy in patients with AMI the feasibility, safety. Methods 110 cases of AMI patients were randomly divided into groups of 54 cases of pre-hospital thrombolysis and the thrombolytic group of 56 cases after admission. Have received treatment outside the hospital immediately after the diagnosis of AMI to the reorganization u intravenous streptokinase 1.5 million, with the same period 56 cases of hospitalized patients with AMI after thrombolytic therapy immediately by the above method. Results The diagnosis ofAMI thrombolytic time：-hospital thrombolysis group （1.48±0.46） hours, hospital thrombolysis group （2.68±1.98） hours. According to clinical criteria to determine the total coronary artery patency rate： 80.8% of pre-hospital thrombolysis group （42/52）, 2 deaths; the hospital thrombolysis group was 64.1% （34/53）, 3 deaths （P〈0.05）. Conclusion The pre-hospital thrombolysis inAMI patients was significantly shorter time to starting thrombolysis, increasing coronary artery patency rate, feasible and safe.